BR112022013005A2 - Coagonistas de glucagon e glp-1 para tratamento da doença renal crônica e da doença renal diabética no diabetes tipo 2 - Google Patents
Coagonistas de glucagon e glp-1 para tratamento da doença renal crônica e da doença renal diabética no diabetes tipo 2Info
- Publication number
- BR112022013005A2 BR112022013005A2 BR112022013005A BR112022013005A BR112022013005A2 BR 112022013005 A2 BR112022013005 A2 BR 112022013005A2 BR 112022013005 A BR112022013005 A BR 112022013005A BR 112022013005 A BR112022013005 A BR 112022013005A BR 112022013005 A2 BR112022013005 A2 BR 112022013005A2
- Authority
- BR
- Brazil
- Prior art keywords
- kidney disease
- glp
- glucagon
- type
- diabetes
- Prior art date
Links
- 208000007342 Diabetic Nephropathies Diseases 0.000 title abstract 5
- 208000033679 diabetic kidney disease Diseases 0.000 title abstract 5
- 102000051325 Glucagon Human genes 0.000 title abstract 4
- 108060003199 Glucagon Proteins 0.000 title abstract 4
- 208000020832 chronic kidney disease Diseases 0.000 title abstract 4
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title abstract 4
- 229960004666 glucagon Drugs 0.000 title abstract 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title abstract 4
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 title abstract 3
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title abstract 3
- 102100040918 Pro-glucagon Human genes 0.000 title abstract 3
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 abstract 4
- YEKUUBPJRPXMBM-PTCFZACGSA-N (2S)-5-[[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-carboxy-1-[[(2S)-1-[[2-(carboxymethylamino)-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-6-oxohexyl]amino]-2-(hexadecanoylamino)-5-oxopentanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)NCC(O)=O)C(O)=O YEKUUBPJRPXMBM-PTCFZACGSA-N 0.000 abstract 2
- 102000009027 Albumins Human genes 0.000 abstract 2
- 108010088751 Albumins Proteins 0.000 abstract 2
- 239000000556 agonist Substances 0.000 abstract 2
- 108091005205 cotadutide Proteins 0.000 abstract 2
- 229940121426 cotadutide Drugs 0.000 abstract 2
- 229940109239 creatinine Drugs 0.000 abstract 2
- 230000003247 decreasing effect Effects 0.000 abstract 2
- 230000002641 glycemic effect Effects 0.000 abstract 2
- 210000002700 urine Anatomy 0.000 abstract 2
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 abstract 1
- 101710176384 Peptide 1 Proteins 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
COAGONISTAS DE GLUCAGON E GLP-1 PARA TRATAMENTO DA DOENÇA RENAL CRÔNICA E DA DOENÇA RENAL DIABÉTICA NO DIABETES TIPO 2. São fornecidos neste documento métodos para melhorar o controle glicêmico, reduzir o peso, diminuir a razão de albumina:creatinina na urina (UACR) e/ou tratar a doença renal diabética (DKD) em um paciente humano com DKD e diabetes mellitus tipo 2 (T2DM) compreendendo administrar um peptídeo agonista de GLP-1/glucagon, tal como Cotadutida. Também são fornecidos neste documento métodos para melhorar o controle glicêmico, reduzir o peso, diminuir a razão de albumina:creatinina na urina (UACR) e/ou tratar a doença renal crônica (CKD) em um paciente humano compreendendo administrar um peptídeo agonista de GLP-1/glucagon, tal como Cotadutida.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062959698P | 2020-01-10 | 2020-01-10 | |
| US202063037832P | 2020-06-11 | 2020-06-11 | |
| US202063089386P | 2020-10-08 | 2020-10-08 | |
| PCT/EP2021/050227 WO2021140174A1 (en) | 2020-01-10 | 2021-01-08 | Glucagon and glp-1 co-agonists for the treatment of chronic kidney disease and diabetic kidney disease in type 2 diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022013005A2 true BR112022013005A2 (pt) | 2022-09-06 |
Family
ID=74205815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022013005A BR112022013005A2 (pt) | 2020-01-10 | 2021-01-08 | Coagonistas de glucagon e glp-1 para tratamento da doença renal crônica e da doença renal diabética no diabetes tipo 2 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210213104A1 (pt) |
| EP (1) | EP4087596A1 (pt) |
| JP (1) | JP2023510523A (pt) |
| KR (1) | KR20220125254A (pt) |
| CN (1) | CN114929258A (pt) |
| AU (1) | AU2021206018A1 (pt) |
| BR (1) | BR112022013005A2 (pt) |
| CA (1) | CA3166027A1 (pt) |
| IL (1) | IL294482A (pt) |
| MX (1) | MX2022008012A (pt) |
| TW (1) | TW202140061A (pt) |
| WO (1) | WO2021140174A1 (pt) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI617574B (zh) | 2012-12-11 | 2018-03-11 | 梅迪繆思有限公司 | 用於治療肥胖之升糖素與ｇｌｐ－１共促效劑 |
| WO2017153575A1 (en) * | 2016-03-10 | 2017-09-14 | Medimmune Limited | Glucagon and glp-1 co-agonists for the treatment of obesity |
| WO2019140025A1 (en) * | 2018-01-12 | 2019-07-18 | Eli Lilly And Company | Combination therapy |
| US20200262887A1 (en) * | 2018-11-30 | 2020-08-20 | Opko Ireland Global Holdings, Ltd. | Oxyntomodulin peptide analog formulations |
-
2021
- 2021-01-05 TW TW110100206A patent/TW202140061A/zh unknown
- 2021-01-08 EP EP21701223.6A patent/EP4087596A1/en active Pending
- 2021-01-08 WO PCT/EP2021/050227 patent/WO2021140174A1/en active Application Filing
- 2021-01-08 KR KR1020227023904A patent/KR20220125254A/ko unknown
- 2021-01-08 JP JP2022540933A patent/JP2023510523A/ja active Pending
- 2021-01-08 IL IL294482A patent/IL294482A/en unknown
- 2021-01-08 BR BR112022013005A patent/BR112022013005A2/pt not_active Application Discontinuation
- 2021-01-08 AU AU2021206018A patent/AU2021206018A1/en active Pending
- 2021-01-08 MX MX2022008012A patent/MX2022008012A/es unknown
- 2021-01-08 CN CN202180008435.9A patent/CN114929258A/zh active Pending
- 2021-01-08 US US17/144,337 patent/US20210213104A1/en not_active Abandoned
- 2021-01-08 CA CA3166027A patent/CA3166027A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021140174A1 (en) | 2021-07-15 |
| JP2023510523A (ja) | 2023-03-14 |
| KR20220125254A (ko) | 2022-09-14 |
| US20210213104A1 (en) | 2021-07-15 |
| CN114929258A (zh) | 2022-08-19 |
| MX2022008012A (es) | 2022-07-21 |
| IL294482A (en) | 2022-09-01 |
| AU2021206018A1 (en) | 2022-08-25 |
| CA3166027A1 (en) | 2021-07-15 |
| EP4087596A1 (en) | 2022-11-16 |
| TW202140061A (zh) | 2021-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Aroda et al. | Efficacy and safety of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin: the LixiLan-L randomized trial | |
| Dungan et al. | A 24‐week study to evaluate the efficacy and safety of once‐weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD‐8) | |
| Giorgino et al. | Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2) | |
| Nauck et al. | Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5) | |
| Ahrén et al. | Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M) | |
| Minze et al. | Benefits of SGLT2 inhibitors beyond glycemic control–a focus on metabolic, cardiovascular and renal outcomes | |
| Wysham et al. | Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial | |
| Scheen | Dulaglutide for the treatment of type 2 diabetes | |
| CY1106971T1 (el) | Συνεργητικη χρηση θειαζολιδινοδιονων με πεπτιδιο-1 που ομοιαζει με γλυκογονο και αγωνιστες αυτου για να θεραπευεται μη-ινσουλινο εξαρτωμενος διαβητης | |
| BRPI0511393A (pt) | moduladores de peptìdeo 1 semelhantes ao glucagon humano e seu uso no tratamento de diabetes e condições relacionadas | |
| Lin et al. | Renal and glucose-lowering effects of empagliflozin and dapagliflozin in different chronic kidney disease stages | |
| Deol et al. | Combination therapy with GLP-1 analogues and SGLT-2 inhibitors in the management of diabesity: the real world experience | |
| Chan et al. | Glycaemic responses in Asian and non-Asian people with type 2 diabetes initiating insulin glargine 100 units/mL: a patient-level pooled analysis of 16 randomised controlled trials | |
| Patil et al. | Glucagon-based therapy: past, present and future | |
| Lingvay et al. | Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once‐weekly glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS‐1 to‐5 studies | |
| Gómez et al. | Combination therapy with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors in older patients with type 2 diabetes: a real-world evidence study | |
| Vasu et al. | Anti-diabetic actions of esculentin-2CHa (1–30) and its stable analogues in a diet-induced model of obesity-diabetes | |
| Lee et al. | Insulin therapy for adult patients with type 2 diabetes mellitus: a position statement of the Korean Diabetes Association, 2017 | |
| BR112022013005A2 (pt) | Coagonistas de glucagon e glp-1 para tratamento da doença renal crônica e da doença renal diabética no diabetes tipo 2 | |
| Kesavadev et al. | CSII as an alternative therapeutic strategy for managing type 2 diabetes: adding the Indian experience to a global perspective | |
| Molitch | Current state of type 2 diabetes management | |
| Fowler | Diabetes treatment, part 3: Insulin and incretins | |
| Reutrakul et al. | Use of U-500 regular insulin via continuous subcutaneous insulin infusion: clinical practice experience | |
| Kitazawa et al. | Combination therapy of glucagon‐like peptide‐1 receptor agonists and insulin for patients who developed diabetes after partial pancreatectomy | |
| Kurtzhals et al. | The role of weight control in the management of type 2 diabetes mellitus: Perspectives on semaglutide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |